Clinical Trial Update: A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating cannabidiol oral solution with vigabatrin as initial therapy for infantile spasms has been terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infantile Spasms

Drugs mentioned

• Cannabidiol Oral Solution (cannabidiol)
• Vigabatrin (Vigabatrin)

Snippet

Sponsor: Radius Pharmaceuticals, Inc. | Conditions: Infantile Spasm | Phase 3 | Status: TERMINATED | Results posted: 2023-06-07